The Filing Desk

Aurinia Pharmaceuticals vs Xeris Biopharma

Aurinia Pharmaceuticals AUPH · Xeris Biopharma XERS · Pharmaceuticals

Xeris Biopharma reported revenue of $292 million in fiscal 2025, about the same as Aurinia Pharmaceuticals' $283 million in fiscal 2025. Aurinia Pharmaceuticals' revenue grew 20.4% in its latest year, and Xeris Biopharma's grew 43.7%. Aurinia Pharmaceuticals had an operating margin of 37.1%, against 8.5% at Xeris Biopharma.

Side by side

Aurinia PharmaceuticalsXeris Biopharma
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$283M$292M
Revenue growth20.4%43.7%
Revenue growth a year, last 5 years41.4%70.3%
Gross margin88.5%—
Operating margin37.1%8.5%
Net margin101.5%0.2%
Free cash flow$135M—
Free cash flow margin47.8%—
Return on capital—19.6%
Net debt to EBITDA—4.2x
Dividends and buybacks$98M$0M
Change in diluted share count−5.1%17.7%
Last close$15.73$16.66
P/E at the last close6.9×—
Insider trades, last 12 monthsbought $25.1 million, sold $546,373sold $4.7 million
Piotroski F-score—7 of 8
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Aurinia PharmaceuticalsXeris Biopharma
Operating margin
Percent of revenue
Aurinia PharmaceuticalsXeris Biopharma
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Aurinia PharmaceuticalsXeris Biopharma

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Aurinia Pharmaceuticals and Xeris Biopharma pages.